MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage many intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Most important trial objectives had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although one of the https://charlesj665whs8.blogmazing.com/30210010/the-5-second-trick-for-z-lehd-fmk